The company's consolidated net sales in the quarter gone by stood at Rs 25,283 crore, down 15.6 per cent from same period last year
The company reported a consolidated net loss of Rs 388.82 crore for the first quarter ended June 30 (Q1) as against a net profit of Rs 274.96 crore in Q1FY20
"We focussed on controlling costs on all fronts and will continue with these efforts for the remaining part of the financial year," Glenmark Pharmaceuticals Chairman and MD Glenn Saldanha said
Total income during the quarter fell by 47 per cent to Rs 610 crore
40% drop in revenue, largely due to absence of IPL and movie distribution
Its operating revenue plunged 51 per cent to Rs 1,297 crores from Rs 2,654 crores last year
The firm's total income during April-June came down to Rs 26,794.68 crore, compared to Rs 27,353.36 crore in the year-ago period
The first quarter numbers are not comparable year on year and quarter on quarter as they come after the merger (Indian Bank +Allahabad Bank)
Berger Paints India Ltd on Friday reported a 91.44 per cent decline in consolidated net profit to Rs 15.09 crore for the quarter ended June, hit by the Covid-19 crisis
Kamdhenu Ltd on Friday posted a sharp decline of 75 per cent in its standalone net profit at Rs 1.5 crore due to reduced income
PBT for the quarter was impacted on account of additional provision of Rs 100 crore towards Covid-19
The company's total income during April-June 2020 came down to Rs 26,794.68 crore, compared with Rs 27,353.36 crore in the year-ago period
Revenue dropped by nearly 45 per cent to Rs 2,403.57 crore during the first quarter ended June 30, 2020 as against Rs 4,40950 crore
Its consolidated revenue from operations during the April-June quarter dropped to Rs 25,283 crore, from over Rs 29, 972 crore in Q1 FY2019-20
The lender had posted a net loss of Rs 217.73 crore in preceding quarter ended March 2020
Revenue from operations in the period under review stood at Rs 2,460.70 crore as against Rs 4,470.82 crore in the corresponding quarter last fiscal, it added
Total income of the company during the quarter under review stood at Rs 1,364.34 crore, down 49.41 per cent from Rs 2,697.27 crore in the year-ago period
The company said the progress of the ongoing capex programme has been delayed due to Covid-19.
Revenue dropped 24 per cent to Rs 1,056.79 crore, EBITDA down 27%
All the 10 constituents of the Nifty Pharma index were trading in the green.